SAB Biotherapeutics (NASDAQ:SABS) Rating Increased to Strong-Buy at Jefferies Financial Group

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by investment analysts at Jefferies Financial Group to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other analysts have also weighed in on the company. Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a research note on Friday, April 10th. Chardan Capital increased their price objective on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, March 11th. HC Wainwright increased their price objective on SAB Biotherapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Rodman & Renshaw reissued a “buy” rating and set a $13.00 price objective on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Finally, Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

SAB Biotherapeutics Stock Performance

NASDAQ:SABS opened at $3.68 on Wednesday. The firm has a market cap of $187.50 million, a PE ratio of -1.74 and a beta of 0.55. SAB Biotherapeutics has a fifty-two week low of $1.60 and a fifty-two week high of $6.60. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.45 and a current ratio of 11.45. The business has a 50 day moving average price of $3.85 and a 200-day moving average price of $3.84.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). Equities research analysts predict that SAB Biotherapeutics will post -1.19 earnings per share for the current year.

Institutional Trading of SAB Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SABS. PNC Financial Services Group Inc. purchased a new stake in SAB Biotherapeutics in the first quarter worth $29,000. ADAR1 Capital Management LLC purchased a new stake in SAB Biotherapeutics in the third quarter worth $30,000. Dimensional Fund Advisors LP purchased a new stake in SAB Biotherapeutics in the third quarter worth $32,000. State of Wyoming purchased a new stake in SAB Biotherapeutics in the fourth quarter worth $34,000. Finally, Virtu Financial LLC purchased a new stake in SAB Biotherapeutics in the third quarter worth $40,000. Hedge funds and other institutional investors own 7.82% of the company’s stock.

Key SAB Biotherapeutics News

Here are the key news stories impacting SAB Biotherapeutics this week:

• Positive Sentiment: Jefferies initiated coverage of SAB Biotherapeutics with a Buy rating, a bullish signal that may be encouraging traders to revalue the stock higher. Jefferies initiates coverage of SAB Biotherapeutics (SABS) with buy recommendation
• Neutral Sentiment: Brookline Capital Markets released updated earnings estimates across 2026-2030, projecting continued losses in the near term but a path to profitability by FY2030. These forecasts provide a longer-term valuation framework, but they do not appear to be a major immediate catalyst. SAB Biotherapeutics Inc SABS
• Negative Sentiment: The company’s most recent quarterly results missed analyst expectations, with EPS of -$0.35 versus consensus of -$0.20, reinforcing concerns about near-term execution and profitability. SAB Biotherapeutics Inc SABS

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.